Osiris Therapeutics Inc., of Columbia, Md., said final two-year results from its Phase I trial evaluating Prochymal for the treatment of acute myocardial infarction found heart attack patients receiving the intravenous therapy had lower rates of adverse events and significantly improved heart function...Also, patients receiving Prochymal had a significant and durable improvement in cardiac function

The study tested a single intramuscular injection in boys with DMD, each patient receiving an injection of the drug into the exterior digitorum brevis muscle of one foot and an injection of saline into the corresponding muscle of the opposite foot to provide an internal treatment comparison

ErepoXen is being developed to treat anemia in patients receiving renal dialysis

The interim results showed a clinical response rate of 50 percent with patients receiving ImmuFact IMP321 the day after weekly paclitaxel compared to 25 percent with paclitaxel alone

SciClone Pharmaceuticals Inc., of Foster City, Calif., said it completed first patient enrollment in its Phase II multicenter, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of SCV-07 for prevention of oral mucositis (OM) in patients receiving radio-chemotherapy for the treatment of head and neck cancer

Results demonstrated that compared to placebo, patients receiving 15 mcg ARX-01 experienced a statistically significant reduction in pain intensity over the study period, based on the worst observation carried forward imputation method, p = 0.015

Compared to placebo, patients receiving lorcaserin experienced statistically significant greater weight loss

Thirty-seven patients remain on ATC, with the longest dosed patients receiving ATC for nearly three years

Patients receiving the combination of twice-daily mitiglinide and metformin experienced a statistically significant additional reduction in hemoglobin A1c (HbA1c) levels compared to patients receiving metformin alone

Metabolex Inc., of Hayward, Calif., reported results from a Phase II trial of MBX-8025 in dyslipidemia, showing that patients receiving the drug experienced a 30 percent reduction in triglycerides and a 20 percent drop in LDL cholesterol vs

The primary endpoint is the complete remission and unconfirmed complete remission rate in patients receiving either pixantrone or another single agent chemotherapeutic drug

The analysis showed that 50 percent of patients receiving the highest dose of DPS-101 achieved a state of "clear to almost clear" at the end of the 12 week study

BioCryst Pharmaceuticals Inc., of Birmingham, Ala., said an exploratory Phase II trial in hospitalized flu patients showed no significant differences between patients receiving 200 mg of intravenous peramivir, 400 mg of intravenous peramivir, or 150 mg of oral oseltamivir, the active ingredient in TamiFlu (F. Hoffmann-La Roche Ltd

The primary objective is to assess the overall tumor response rate in patients receiving the combination therapy

The findings from the SONIC trial showed that a significantly greater proportion of patients with moderate to severe Crohn's disease receiving Remicade (infliximab), either in combination with azathioprine or as monotherapy, experienced steroid-free remission and mucosal healing compared with patients receiving azathioprine alone

In an earlier trial, at a median follow-up of 30 months, the tumor recurrence rate for patients receiving the optimal dose was much lower than that of patients receiving suboptimal doses (3.4 percent vs. 12.9 percent...Patients receiving monthly doses of VEGF Trap-Eye of either two or 0.5 mg for 12 weeks followed by physicians research network (PRN) dosing achieved mean improvements in visual acuity vs

MediciNova Inc., of San Diego, said data from a two-year, 297-patient Phase II trial of MN-166 in multiple sclerosis showed that sustained disability progression was significantly less likely (by about 50 percent) in patients receiving MN-166 at either 30 mg or 60 mg per day for 24 months than in those receiving the drug for 12 months

The 12-month survival rate of patients treated with Gemcitabine alone was 17 percent, while it was 22 percent (low dose), 36 percent (medium dose) and 33 percent (high dose) for patients receiving EndoTAG-1 in combination with Gemcitabine

The first trial showed a decrease in number of headache days that was significantly greater in patients receiving Botox vs...patients receiving placebo (p = 0.002